Consequently, Rabeprazole and Pantoprazole are potential novel inhibitors of FOXM1 and may be used as FOXM1-targeted cancer therapy in treatment of breast cancer and other FOXM1-driven cancers. The gene discussed is FOXM1; the disease is breast carcinoma.